Remove 2020 Remove Communication Remove Compounding
article thumbnail

Open communication helps ulcerative colitis patients through COVID-19

pharmaphorum

Gastroenterologist Dr Séverine Vermeire explains how lockdowns and communication changes over COVID-19 are taking their toll on ulcerative colitis patients and how we can best support them in the new normal. The COVID-19 pandemic might have changed everything about how we communicate, but as humans we still crave social interaction.

article thumbnail

The digital transformation of pharma’s physician engagement strategies

pharmaphorum

The pandemic has ushered in a number of major changes to healthcare systems, notably in the ways in which pharmaceutical companies communicate, visit and engage with physicians. The threat of disease spread and other risk factors from COVID-19 have only compounded this. How engagement with HCPs will evolve in the future.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Utilising content metrics to improve digital engagement

pharmaphorum

Using content metrics, companies can understand how their current content is received and engaged with, which will, in turn, helps clarify the most effective and efficient ways to connect and communicate with their audience in the future, resulting in increased speed to market and effective content engagement.

article thumbnail

COVID-19 and the digital pharma marketing revolution

pharmaphorum

Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications. Until 2020, pharma had lagged other industries in its investment in digital marketing. billion on digital advertising in 2020, based on figures from the first nine months of the year.

article thumbnail

Unlocking the potential in rare disease research with decentralised trials

pharmaphorum

The report found that people’s willingness to take part in clinical trials in 2020 fell dramatically compared to previous years – however that survey was conducted with the wider public while the Raremark survey focused specifically on people with rare diseases. Research and development will always be important to rare disease patients.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. Brussels; 2020. London: Office of Health Economics; 2020. References.

article thumbnail

Too Much of a Good Thing? Unpacking the Rise of Polypharmacy in Seniors

PharmD Live

“Polypharmacy and Elderly Patients: A 2020 Study,” Journal of Geriatric Care ). Residents of Long-Term Care Facilities: Patients in these settings experience a polypharmacy rate approximately 50% higher than their counterparts living independently in the community. Reference: Smith, J. & & Doe, A. & Hamilton, L.